Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting
- PMID: 16918408
- DOI: 10.2174/138161206777947740
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting
Abstract
Integrins constitute an important class of cell adhesion receptors responsible not only for cell-matrix adhesion but also for signaling bidirectionally across the membrane. Integrins are involved in many biological processes such as angiogenesis, thrombosis, inflammation, osteoporosis and cancer. Integrins thus play a key role in many severe human diseases. In this review we will describe recent research and development of RGD-containing integrin ligands for medical applications including drug design, radiolabeling, drug targeting, as well as biomaterial research. Many ligands have been developed for targeting the avb3 integrin in order to block angiogenesis or osteoporosis, but there are also other integrins like avb5 and a5b1 which become more and more interesting for similar purposes. aIIbb3 constitutes a potent target in thrombosis therapy; but the search for suitable ligands is still ongoing. We will reconstruct the drug development process for these integrin subtypes considering selected examples with focus on structure based design. Different structural requirements are pointed out concerning integrin activity and particularly the selectivity towards the distinct integrin types. Furthermore, we will show recent progress in tumor and thrombosis imaging based on radiolabeled RGD-containing ligands binding avb3 or aIIbb3, respectively. Additionally further advances in biomaterial research are presented. We describe the coating of different implant materials with various avb3 recognizing ligands for the purpose of increasing cell attachment and biocompatibility.
Similar articles
-
Integrins in drug targeting-RGD templates in toxins.Curr Pharm Des. 2006;12(22):2749-69. doi: 10.2174/138161206777947713. Curr Pharm Des. 2006. PMID: 16918409 Review.
-
Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.Chembiochem. 2021 Apr 6;22(7):1151-1160. doi: 10.1002/cbic.202000626. Epub 2020 Nov 27. Chembiochem. 2021. PMID: 33140906 Review.
-
Recent progress in biomedical applications of RGD-based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review.J Biomed Mater Res A. 2020 Apr;108(4):839-850. doi: 10.1002/jbm.a.36862. Epub 2019 Dec 30. J Biomed Mater Res A. 2020. PMID: 31854488
-
Ligands for mapping alphavbeta3-integrin expression in vivo.Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b. Acc Chem Res. 2009. PMID: 19489579
-
RGD and other recognition sequences for integrins.Annu Rev Cell Dev Biol. 1996;12:697-715. doi: 10.1146/annurev.cellbio.12.1.697. Annu Rev Cell Dev Biol. 1996. PMID: 8970741 Review.
Cited by
-
Paenibacillus arenilitoris sp. nov., isolated from seashore sand and genome mining revealed the biosynthesis potential as antibiotic producer.Antonie Van Leeuwenhoek. 2022 Nov;115(11):1307-1317. doi: 10.1007/s10482-022-01773-1. Epub 2022 Aug 26. Antonie Van Leeuwenhoek. 2022. PMID: 36018400
-
Biodegradable Silk Fibroin Nanocarriers to Modulate Hypoxia Tumor Microenvironment Favoring Enhanced Chemotherapy.Front Bioeng Biotechnol. 2022 Jul 22;10:960501. doi: 10.3389/fbioe.2022.960501. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35935500 Free PMC article.
-
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.Anticancer Agents Med Chem. 2010 Dec;10(10):753-68. doi: 10.2174/187152010794728639. Anticancer Agents Med Chem. 2010. PMID: 21269250 Free PMC article. Review.
-
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT.Theranostics. 2011 Jan 18;1:58-82. doi: 10.7150/thno/v01p0058. Theranostics. 2011. PMID: 21547153 Free PMC article.
-
Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.J Control Release. 2012 Apr 10;159(1):2-13. doi: 10.1016/j.jconrel.2011.10.023. Epub 2011 Oct 26. J Control Release. 2012. PMID: 22056916 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources